Mounjaro 0.25 mg: the starter dose explained

Why does Mounjaro start at 0.25 mg rather than a higher dose?

Tirzepatide works by activating two gut-hormone receptors, GIP and GLP-1, which slow how quickly the stomach empties and reduce appetite signals. When you introduce that kind of activity for the first time, the digestive system needs time to adapt. Starting at a low level keeps the most common side effects (nausea, loose stools, and indigestion) within a range most people can manage while carrying on with daily life.

A question our prescribers hear most weeks is whether staying on 0.25 mg for longer will produce more weight loss. The honest answer is that the evidence does not support that idea. The dose is built for comfort, not for effect. The weight-loss data from the SURMOUNT programme, published in the New England Journal of Medicine, was generated at maintenance doses of 5 mg, 10 mg and 15 mg, not at the starting level. Expecting significant results from 0.25 mg alone would set an unfair benchmark for the weeks ahead.

None of this means the first four weeks are wasted. Your prescriber is watching how your body responds, and that information shapes every subsequent dose decision. Think of it as a calibration period rather than a holding pattern.

What exactly is in the 0.25 mg pen, and how is the dose delivered?

There is no separate pen manufactured at 0.25 mg. The dose comes from the Mounjaro 2.5 mg KwikPen, which is pre-set to deliver four weekly injections at 0.25 mg each. Once all four doses have been administered over four weeks, the pen is finished and disposed of in a sharps container, you do not adjust the device yourself.

Injection technique is straightforward. Common sites are the abdomen, the front of the thigh, or the upper arm, and rotating between them helps avoid skin irritation at a single spot. For full details on storage temperatures, injection steps and what to do if a dose is missed, the Mounjaro Patient Information Leaflet on the eMC is the authoritative reference, it is updated by the manufacturer and reflects the current UK licence. Your prescriber and our aftercare team are also available seven days a week if a practical question comes up between appointments.

Because the pen contains four pre-set doses, it is important not to try to alter the injection mechanism. The device locks after each weekly use and is not designed to be re-set.

When does the dose increase, and who decides?

The standard licensed schedule moves from 0.25 mg to 5 mg after four weeks, then continues upward in 4-weekly steps (7.5 mg, 10 mg, 12.5 mg, and finally 15 mg) if the previous dose has been well tolerated and the prescriber judges an increase appropriate. You can read more about how the full dose range is structured on the Mounjaro dosage overview page.

The prescriber decides, not the calendar. If you experience significant side effects at 0.25 mg, the sensible clinical response is to stay at that level a little longer rather than push through. Equally, if tolerance is good and no contraindications emerge, moving to the next step on schedule is normal. There is no automatic titration at nume, a clinician reviews each step before any change is made.

It is also worth knowing that some people's journeys do not follow the standard ladder exactly. Circumstances like illness, a planned procedure, or pregnancy mean the prescriber may pause, reduce, or stop treatment. Those decisions are always made case by case. If you are curious about what treatment costs across the full dose schedule, that information is set out separately and honestly on our pricing page.

What side effects are most likely at this dose?

The most common effects reported with tirzepatide are gastrointestinal: nausea, burping, constipation, loose stools and indigestion. At 0.25 mg these tend to be milder than at higher doses, which is precisely the point of beginning here. For many people they are barely noticeable; for others they are present but manageable, usually settling after the first week or two as the body adjusts.

The NHS tirzepatide medicines page lists both common and less common effects clearly and is updated in line with current UK guidance, it is a reliable first reference. If you are already thinking ahead to later stages of treatment, our pages covering tirzepatide 2.5 mg and the broader dose journey and 4 mg Mounjaro explain what to expect as the dose increases. A few signals warrant urgent medical attention regardless of dose: severe or persistent stomach pain that spreads to the back (a potential indicator of pancreatitis), signs of a serious allergic reaction such as swelling around the face or difficulty breathing, and symptoms of significant dehydration following prolonged vomiting or diarrhoea. If any of these occur, seek medical help promptly rather than waiting for your next scheduled review.

Suspected side effects can be reported directly to the MHRA via the Yellow Card scheme, patients as well as healthcare professionals can submit reports, and doing so helps build the safety picture for newer medicines like tirzepatide, which carries a Black Triangle (▼) status indicating it is under enhanced monitoring. If you are ready to find out whether treatment is right for you, starting a free consultation with our prescribers is the next step.